You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Introgen Therapeutics, Inc., a former biopharmaceutical company engaged in the discovery, development, and commercialization of targeted molecular therapies for the treatment of cancer and other diseases, filed for relief under Chapter 11 in December 2008. On November 26, 2008, regulatory challenges, which the Company faced with its Advexin filings, the Company’s overall financial condition, and a difficult external financing marketplace led to the resignation of almost all of the senior management of the Company as well as a drastic down-sizing of personnel and expenditures. On December 9, 2008, the Company's shares were delisted from NASDAQ.
| Ticker: | INGN |
| ISIN: | US46119F1075 |
| Address: |
301 Congress Avenue Suite 1850 |
| Austin, TX, 78701, USA | |
| Website: | Introgen Therapeutics, Inc. |
| Phone #: | 512-7089310 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Pharmaceutical & Medicine Manufacturing |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.